D-α-methyl-β-acetylthiopropionyl chloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-α-methyl-β-acetylthiopropionyl chloride
• 英文别名: 2-Methyl-4-oxopentanethioyl chloride
• 化学式: C₆H₉ClOS
• 分子量: 164.656
• InChiKey: KREZZZHPQXGMQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  D-α-methyl-β-acetylthiopropionyl chloride 、 L-脯氨酸 在 盐酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 以89%的产率得到N-(D-α-methyl-β-acetylthiopropionyl)-L-proline
  参考文献：
  名称：

  Process for producing

  摘要：

  一种高效、便捷的方法，经济地生产高产量、高质量的卡托普利，其杂质含量明显降低，熔点高，且用于合成的中间体仅含有少量前体杂质，具有出色的品质。该方法包括将酸卤和L-脯氨酸置于Schotten-Baumann反应中，并通过处理水介质溶液来消除作为副产物形成的前体杂质，所述前体杂质由通式（5）或（6）表示，在Schotten-Baumann反应期间或之后，使用活性炭或结晶进行脱酰化处理。在该式中，R.sup.1代表酰基，n为2至4的整数。##STR1##

  公开号：

  US05917055A1

文献信息

• Angiotensin converting enzyme inhibitors
  申请人：UNIVERSITY OF MIAMI

  公开号：EP0036713A2

  公开（公告）日：1981-09-30

  Novel inhibitors of angiotensin converting enzyme having the general formula R-A-S-Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

  公开了通式为 R-A-S-Z 的新型血管紧张素转换酶抑制剂，它们是血管紧张素转换酶的强效抑制剂，也是有用的抗高血压药物。
• Octahydro-2-(omega-mercaptoalkanoyl)3-oxo-1H-isoindole-1-carboxylic acids and esters
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0093805A1

  公开（公告）日：1983-11-16

  The invention provides octahydro-2-(w-mercaptoalka- noyl)-1H-isoindole-1-carboxylic acids and esters having the formula wherein R is hydrogen or lower alkyl, R, is hydrogen, lower alkyl or benzyl, R2 is hydrogen or R3-CO- (wherein R3 is lower alkyl, heteroaryl containing 4 to 9 carbon atoms and one or two nitrogen, oxygen or sulfur atoms, phenyl or substituted phenyl having one or two substituents selected from fluorine, chlorine, bromine, lower alkyl and lower alkoxy), n is 0 or 1, and X is two hydrogen atoms or one oxygen atom, wherein lower alkyl and lower alkoxy include straight or branched groups containing 1 to 4 carbon atoms; and pharmaceutically acceptable salts thereof when R is hydrogen and/or when R3 is heteroaryl containing 1 or 2 nitrogen atoms. The acids and esters, and their salts, are useful as antihypertensive agents.

  本发明提供八氢-2-(w-巯基)-1H-异吲哚-1-羧酸及其酯，其式为 其中 R 是氢或低级烷基，R，是氢、低级烷基或苄基，R2 是氢或 R3-CO-（其中 R3 是低级烷基、含有 4 至 9 个碳原子和 1 或 2 个氮、氧或硫原子的杂芳基、具有 1 或 2 个选自氟、氯、溴、低级烷基和低级烷氧基的取代基的苯基或取代苯基），n 是 0 或 1，X 是 2 个氢原子或 1 个氧原子，其中低级烷基和低级烷氧基包括含有 1 至 4 个碳原子的直链或支链基团；及其药学上可接受的盐，当 R 为氢和/或 R3 为含有 1 或 2 个氮原子的杂芳基时。这些酸和酯及其盐可用作降压药。
• NOVEL PYRIDAZINONE DERIVATIVES
  申请人：MITSUI TOATSU KAGAKU KABUSHIKI KAISHA

  公开号：EP0107735A1

  公开（公告）日：1984-05-09

  Pyridazinone derivatives represented by the general formula: wherein R1 and R2 each represents H or lower alkyl, A represents (i) phenyl, furyl, thienyl or pyridyl (optionally having one to three substituents selected from among NH2, NO2, lower alkanoylamino, OH, lower alkanoyloxy, sulfamoyl, and halogen, (ii) (wherein R3 represents H, lower alkyl, substituted lower alkyl (having a phenyl, hydroxyphenyl, lower alkylmercapto, benzylmercapto, guanidino, nitroguanidino, indolyl, carbamoyl or carboxy group as a substituent), R4 represents H or lower alkyl, R6 represents H, lower alkyl, lower alkanoyl, benzoyl or benzoyloxycarbonyl, or R3 and R4 are taken together to form or or (iii) (wherein R5 to R8 each represents H or lower alkyl, B represents 0 or S, R9 represents H or lower alkanoyl, and n represent 0 or 1). These compounds show a hypotensive effect, a blood platelet agglutination-preventing effect, and a cardiac muscle contraction-strengthning effect.

  由通式代表的哒嗪酮衍生物： 其中 R1 和 R2 各自代表 H 或低级烷基，A 代表 (i) 苯基、呋喃基、噻吩基或吡啶基（任选具有选自 NH2、NO2、低级烷酰氨基、OH、低级烷酰氧基、氨基磺酰基和卤素中的一至三个取代基），(ii) (其中 R3 代表 H、低级烷基、取代的低级烷基（具有苯基、羟基苯基、低级烷基巯基、苄基巯基、胍基、硝基胍基、吲哚基、氨基甲酰基或羧基作为取代基），R4 代表 H 或低级烷基，R6 代表 H、低级烷基、低级烷酰基、苯甲酰基或苯甲酰氧基羰基，或 R3 和 R4 合在一起形成 或 或 (iii) (其中 R5 至 R8 各自代表 H 或低级烷基，B 代表 0 或 S，R9 代表 H 或低级烷酰基，n 代表 0 或 1）。这些化合物具有降血压作用、防止血小板凝集作用和增强心肌收缩力的作用。
• PROCESS FOR PRODUCING N-(D-$g(a)-METHYL-$g(b)-MERCAPTOPROPIONYL)-L-PROLINE AND INTERMEDIATES THEREOF
  申请人：KANEKA CORPORATION

  公开号：EP0802182A1

  公开（公告）日：1997-10-22

  A highly convenient and efficient process for economically producing in a high yield high-quality captopril which is remarkably reduced in the content of impurities and has a high melting point and intermediates for synthesizing the same which contain only a small amount of precursors as impurities and have excellent qualities. The process comprises subjecting an acid halide and an L-proline to the Schotten-Baumann reaction and eliminating the impurities formed as the by-products in the form of the precursors represented by general formula (5) or (6) by treating, during or after the Schotten-Baumann reaction, the aqueous medium solution with active carbon or crystallization followed by deacylation. In the formula, R1 represents acyl and n represents an integer of from 2 to 4.

  一种非常方便和高效的工艺，可以经济地高产率生产出杂质含量显著降低、熔点高的高质量卡托普利，以及仅含有少量前体杂质、质量上乘的合成卡托普利的中间体。该工艺包括将酸卤化物和 L-脯氨酸进行肖滕-鲍曼反应，并通过在肖滕-鲍曼反应期间或之后用活性碳处理水介质溶液或结晶，然后进行脱乙酰化，以通式（5）或（6）代表的前体形式消除作为副产物形成的杂质。式中，R1 代表酰基，n 代表 2 至 4 的整数。
• SIMPLE PROCESS FOR PRODUCING HIGH-QUALITY CAPTOPRIL
  申请人：KANEKA CORPORATION

  公开号：EP0889031A1

  公开（公告）日：1999-01-07

  A process for producing captopril of the following formula (1) comprising subjecting a substrate compound of the following general formula (2) to hydrolysis reaction in aqueous medium to remove RCO group and isolating, said hydrolysis reaction in aqueous medium being conducted in the presence of a strong acid at pH not over 1 and a reaction temperature not below 40°C.

  一种生产下式(1)卡托普利的工艺，包括将下式(2)的底物化合物在水介质中进行水解反应以除去 RCO 基团并分离，所述水介质中的水解反应在强酸存在下进行，pH 值不超过 1，反应温度不低于 40℃。